The U.S. Court of Appeals for the Third Circuit has upheld a Pennsylvania federal judge’s dismissal of antitrust claims against GlaxoSmithKline over a patent infringement settlement with generic drugmakers allegedly aimed at delaying market entry of generic versions of the popular antidepressant Wellbutrin XL.
But the appeals court’s reasoning for upholding those rulings has not yet been revealed to the public. The court temporarily issued its Wednesday opinion under seal and, in a separate order, gave the parties until Aug. 15 to agree on proposed redactions.
